342 related articles for article (PubMed ID: 24848754)
1. Next-generation phosphate binders: focus on iron-based binders.
Nastou D; Fernández-Fernández B; Elewa U; González-Espinoza L; González-Parra E; Sanchez-Niño MD; Ortiz A
Drugs; 2014 Jun; 74(8):863-77. PubMed ID: 24848754
[TBL] [Abstract][Full Text] [Related]
2. Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
Negri AL; Ureña Torres PA
Clin Kidney J; 2015 Apr; 8(2):161-7. PubMed ID: 25815172
[TBL] [Abstract][Full Text] [Related]
3. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
Cozzolino M; Funk F; Rakov V; Phan O; Teitelbaum I
Curr Drug Metab; 2014; 15(10):953-65. PubMed ID: 25658128
[TBL] [Abstract][Full Text] [Related]
5. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sprague SM; Floege J
Expert Opin Pharmacother; 2018 Jul; 19(10):1137-1148. PubMed ID: 29985725
[TBL] [Abstract][Full Text] [Related]
6. Phosphate binders in chronic kidney disease: an updated narrative review of recent data.
Floege J
J Nephrol; 2020 Jun; 33(3):497-508. PubMed ID: 31865608
[TBL] [Abstract][Full Text] [Related]
7. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sprague SM; Ketteler M
Expert Opin Drug Saf; 2021 Dec; 20(12):1463-1472. PubMed ID: 34511018
[TBL] [Abstract][Full Text] [Related]
8. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
Locatelli F; Del Vecchio L
J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
[TBL] [Abstract][Full Text] [Related]
9. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
Bousher A; Al-Makki A; Sutton J; Shepler B
Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
[TBL] [Abstract][Full Text] [Related]
10. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
[TBL] [Abstract][Full Text] [Related]
11. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
12. Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
Zhu Y; Rao J; Liao X; Ou J; Li W; Xue C
Int Urol Nephrol; 2021 Sep; 53(9):1899-1909. PubMed ID: 33675476
[TBL] [Abstract][Full Text] [Related]
13. Treating hyperphosphatemia - current and advancing drugs.
Ketteler M; Liangos O; Biggar PH
Expert Opin Pharmacother; 2016 Oct; 17(14):1873-9. PubMed ID: 27643443
[TBL] [Abstract][Full Text] [Related]
14. Novel iron-based phosphate binders in patients with chronic kidney disease.
Shah HH; Hazzan AD; Fishbane S
Curr Opin Nephrol Hypertens; 2015 Jul; 24(4):330-5. PubMed ID: 26050119
[TBL] [Abstract][Full Text] [Related]
15. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
[TBL] [Abstract][Full Text] [Related]
16. The Role of Iron-Based Phosphate Binder in the Treatment of Hyperphosphatemia.
Daoud K; Badran H; Anwar N; Nguyen T
Nephrol Nurs J; 2023; 50(2):140-144. PubMed ID: 37074939
[TBL] [Abstract][Full Text] [Related]
17. An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles.
Ogata H; Takeshima A; Ito H
Expert Opin Drug Saf; 2022 Jul; 21(7):947-955. PubMed ID: 35180026
[TBL] [Abstract][Full Text] [Related]
18. [Current approaches in the treatment of hyperphosphatemia in chronic kidney disease].
Matuszkiewicz-Rowińska J; Kościelska M
Wiad Lek; 2017; 70(6 pt 2):1161-1165. PubMed ID: 29533905
[TBL] [Abstract][Full Text] [Related]
19. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
Greig SL; Plosker GL
Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
[TBL] [Abstract][Full Text] [Related]
20. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
